Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
Robert M Burkes,1,2 Ralph J Panos1,2 1University of Cincinnati Division of Pulmonary, Critical Care, and Sleep Medicine, Cincinnati, OH, USA; 2Department of Pulmonary, Critical Care, and Sleep Medicine, Cincinnati Veterans’ Affairs Medical Center, Cincinnati, OH, USACorrespondence: Ralph J...
Saved in:
Main Authors: | Burkes RM (Author), Panos RJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA)
by: Bjermer L, et al.
Published: (2015) -
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
by: Ora J, et al.
Published: (2020) -
Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
by: Melissa H. Roberts, et al.
Published: (2019) -
LONG-TERM AZITHROMYCIN TREATMENT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: Vanya Kostadinova, et al.
Published: (2020) -
Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist
by: Hélène Salvator, et al.
Published: (2020)